Rana Kassas, Legal Expert in Clinical Research – International Affairs at Policies at EORTC, shared on LinkedIn:
“I had the pleasure of presenting our article ‘Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland’ (Denis Lacombe, Stéphanie Kromar) at the ECO Summit 2026, as one of the Top 3 selected abstracts.

Denis Lacombe and Stéphanie Kromar (LinkedIn)
A great opportunity to share perspectives on low-intervention clinical trials LICTs and their regulation under the proposed EU Biotech Act.
The EORTC – European Organisation for Research and Treatment of Cancer key message is clear: the regulatory framework for low-risk clinical trials should be proportionate to their actual risk, their established use in clinical practice, and their added value for public health.
In this context, we presented the EORTC’s two recommendations for LICT reform under the proposed Biotech Act:
- Clarify eligibility criteria under Article 2.2 CTR: Further define low-intervention clinical trials based on established clinical practice, ensuring that trials genuinely meeting these criteria can benefit from a proportionate regulatory framework.
- Simplify regulatory requirements under Article 6 CTR: Introduce a proportionate CTIS review process, limited to Part II Ethics Committee review, to reduce unnecessary regulatory burdens while maintaining appropriate safeguards.
Title: Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland
Authors: Rana Kassas, Denis Lacombe, Stéphanie Kromar
Thank you to the European Cancer Organisation summit organisers for this opportunity and to all those who contributed to the insightful discussions.
Looking forward to continue working together towards a more proportionate, efficient, and patient-centred clinical research environment in Europe.”
EORTC – European Organisation for Research and Treatment of Cancer added:
“A great achievement to have this work selected among the Top 3 abstracts at European Cancer Summit 2026!
Congratulations to Rana Kassas, EORTC’s legal expert in clinical research, on presenting EORTC’s work on the need for a more proportionate EU regulatory framework for low-intervention clinical trials, and to Denis Lacombe and Stéphanie Kromar for their valuable contributions.
An important discussion on reducing unnecessary regulatory barriers while ensuring that clinical research remains safe, efficient and patient-centred.”

You can also read: